Open Access Highly Accessed Research

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire

Esteban Dauden1, Enrique Herrera2, Lluis Puig3, José Luis Sánchez-Carazo4, Jaime Toribio5, Ma Teresa Caloto6, Gonzalo Nocea6*, Montse Roset6 and Nuria Lara7

Author Affiliations

1 Department of Dermatology, Hospital Universitario de la Princesa, Madrid, Spain

2 Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain

3 Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

4 Department of Dermatology, Hospital General de Valencia, Valencia, Spain

5 Department of Dermatology, CHU Santiago (Hospital Gil Casares), Santiago de Compostela, Spain

6 Outcomes Research, MSD, Madrid, Spain

7 IMS Health, Health Economics and Outcomes Research, Barcelona, Spain

For all author emails, please log on.

Health and Quality of Life Outcomes 2012, 10:56  doi:10.1186/1477-7525-10-56

Published: 24 May 2012



Several questionnaires have been used to measure health related quality of life (HRQoL) in patients with psoriasis, few have been adapted for use in Spain; none of them was developed specifically for the Spanish population. The purpose of the study was to validate and assess the sensitivity to change of a new questionnaire to measure HRQOL in patients with psoriasis (PSO-LIFE).


Observational, prospective, multicenter study performed in centers around Spain. Patients with active or inactive psoriasis completed the PSO-LIFE together with other Dermatology Quality of Life Index (DLQI) and Psoriasis Disability Index (PDI). A control group of patients with urticaria or atopic dermatitis was also included. Internal consistency and test-retest reliability of the PSO-LIFE were assessed by calculating Cronbach’s alpha and Intraclass Correlation Coefficient (ICC). Validity was assessed by examining factorial structure, the capacity to discriminate between groups, and correlations with other measures. Sensitivity to change was measured using effect sizes.


The final sample included for analysis consisted of 304 patients and 56 controls. Mean (SD) age of psoriasis patients was 45.3 (14.5) years compared to 38.8 (14) years for controls (p < 0.01). Cronbach’s alpha for the PSO-LIFE was 0.95 and test-retest reliability using the ICC was 0.98. Factor analysis showed the questionnaire to be unidimensional. Mean (SD) PSO-LIFE scores differed between patients with psoriasis and controls (64.9 [22.5] vs 69.4 [17.3]; p < 0.05), between those with active and inactive disease (57.4 [20.4] vs 76.4 [20.6]; p < 0.01), and between those with visible and non-visible lesions (63.0 [21.9] vs. 74.8 [23.9]; p < 0.01). The correlation between PSO-LIFE and PASI scores was moderate (r = −0.43) while correlations with DLQI and PDI dimensions ranged from moderate to high (between 0.4 and 0.8). Effect size on the PSO-LIFE in patients reporting ‘much improved’ health status at study completion was 1.01 (large effect size).


The present results provide substantial support for the reliability, validity, and responsiveness of the PSO-LIFE questionnaire in the population for which it was designed.

Psoriasis; Quality of life; Questionnaire; Validation